Drug Trial Radar · NCT07570082
Drug-Drug Interaction Study of Atumelnant in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
May 28, 2026
Primary completion
Jun 30, 2026
Study completion Jul 30, 2026
Sponsor
- Lead sponsor
- Crinetics Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- May 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to evaluate the impact of strong CYP3A4 induction on the pharmacokinetics (PK) of atumelnant, as well as the effect of atumelnant on CYP3A4, P-gp, and MATE1/2-K substrates in healthy participants.
Conditions
- Healthy Volunteers
Interventions
AtumelnantDrug
Atumelnant, tablets
CarbamazepineDrug
CYP3A4 inducer
MidazolamDrug
CYP3A4 substrate
DigoxinDrug
P-gp substrate
MetforminDrug
MATE1/2-K substrate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Pharmacokinetics (AUC 0-last)Time frame: Up to Day 34
- Cohort 1: Pharmacokinetics (AUC 0-inf)Time frame: Up to Day 34
- Cohort 1: Pharmacokinetics (Cmax)Time frame: Up to Day 34
- Cohort 2: Pharmacokinetics (AUC 0-last)Time frame: Up to Day 21
- Cohort 2: Pharmacokinetics (AUC 0-inf)Time frame: Up to Day 21
- Cohort 2: Pharmacokinetics (Cmax)Time frame: Up to Day 21
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Crinetics Study Site
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.